tbuckley/cabot-search huggingface dataset:
Deferasirox Chelation Therapy in Transfusion Dependent MDS Patients. Final Report From the Gimema MDS0306 Prospective Trial
Authors: Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci, Carlo Finelli, Nicola Cantore, Giovanni Quarta, Alfonso Maria D'Arco, Nicola Cascavilla, Giuseppe Saglio, Alessandro Levis, Martina Pettinau, Giovanni Caocci, Enrica Morra, Daniele Vallisa, Giancarlo Latte, Alfonso Piciocchi, Katia Bontempi, Marco Vignetti, Sante Tura
Journal: Blood (2012)
PU.1 Is Indispensable for Development of Mature Dendritic Cells and Their Function That Plays a Critical Role in Maintenance of Normal T Cell Pool.
Authors: Tadafumi Iino, Yong Jeong, Shin-ichi Mizuno, Kentaro Kohno, Kyoko Ito, Daniel G. Tenen, Boris Reizis, Koichi Akashi
Journal: Blood (2009)
Genetics of Combined Pituitary Hormone Deficiency: Roadmap into the Genome Era
Authors: Qing Fang, Akima S. George, Michelle L. Brinkmeier, Amanda H. Mortensen, Peter Gergics, Leonard Y. M. Cheung, Alexandre Z. Daly, Adnan Ajmal, María Ines Pérez Millán, A. Bilge Ozel, Jacob O. Kitzman, Ryan E. Mills, Jun Z. Li, Sally A. Camper
Journal: Endocrine Reviews (2016)

The genetic basis for combined pituitary hormone deficiency (CPHD) is complex, involving 30 genes in a variety of syndromic and nonsyndromic presentations. Molecular diagnosis of this disorder is valuable for predicting disease progression, avoiding unnecessary surgery, and family planning. We expect that the application of high throughput sequencing will uncover additional contributing genes and eventually become a valuable tool for molecular diagnosis. For example, in the last 3 years, six new genes have been implicated in CPHD using whole-exome sequencing. In this review, we present a historical perspective on gene discovery for CPHD and predict approaches that may facilitate future gene identification projects conducted by clinicians and basic scientists. Guidelines for systematic reporting of genetic variants and assigning causality are emerging. We apply these guidelines retrospectively to reports of the genetic basis of CPHD and summarize modes of inheritance and penetrance for each of the known genes. In recent years, there have been great improvements in databases of genetic information for diverse populations. Some issues remain that make molecular diagnosis challenging in some cases. These include the inherent genetic complexity of this disorder, technical challenges like uneven coverage, differing results from variant calling and interpretation pipelines, the number of tolerated genetic alterations, and imperfect methods for predicting pathogenicity. We discuss approaches for future research in the genetics of CPHD.
OP0157 Prevalence and Significance of MEFV Gene Mutations in Patients with Gouty Arthritis
Authors: S. Kobak, A. Karaarslan, I. Kaya, N. Intepe, M. Orman, A. Berdeli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gouty arthritis is a chronic erosive autoinflammatory disease. Pyrin has anti-inflammatory effects in the regulation of inflammasome and is encoded by the MEFV gene. MEFV gene mutations trigger inflammatory cascade and cause familial Mediterranean fever The relationship between different rheumatic diseases and the MEFV gene mutations was demonstrated. <h3>Objectives</h3> The aim of this study was to determine the frequency of MEFV gene mutation in patients with gouty arthritis and identify a possible correlation with disease phenotype. <h3>Methods</h3> Ninety-three patients with gouty arthritis and 102 healthy controls, compatible with age, gender and ethnicity, were included in the study. MEFV gene was investigated by PCR method. <h3>Results</h3> Out of 93 patients with gouty arthritis, 36 (38.7%) showed MEFV gene mutation carriage, whereas 20.6% in healthy control group. Distribution of mutations identified in patients with gouty arthritis was as; R202Q in 18 (19.3%), E148Q in 5 (5.4%), K695R in 4 (4.3%), M680I in 2 (2.1%), V726A in 2 (2.1%), P369S in 2 (2.1%), R408Q in 2 (2.1%), M694V in 1 (1.1%), respectively. Three patients were identified with compound heterozygosity. Distribution of MEFV gene mutation carriage in healthy controls was; E148Q in 11 (10.7%), M694V in 2 (1.9%), M694I in 1 (0.9%), M680I in 2 (1.9%), V726A in 1 (0.9%), A744S in 1 (0.9%), K695R in 2 (1.9%), and P369S in 1 (0.9%) pateints, respectively. Higher MEFV gene mutation carrier frequency was observed in patients with gouty arthritis, compared with the control group (p=0.009). Heterozygous R202Q was the most common mutation detected in patients with gouty arthritis while heterozygous E148Q in healthy control group. Statistically significant difference was not detected between clinical findings of gouty arthritis and the MEFV gene mutations (p&gt;0.05). <h3>Conclusions</h3> We determined higher prevalence of MEFV gene mutation in patients with gouty arthritis compared with the healthy control group. The most frequently detected mutation was heterozygous R202Q wheras E148Q in healthy controls. High carriage rates of MEFV gene mutation in gouty arthritis suggests that it may play an important role in the pathogenesis of the disease and predisposition to the disease. In this regard, prospective studies are needed with larger series of patients. <h3>Disclosure of Interest</h3> None declared
PWE-034 Hospitalisation for PBC: A UK-PBC Analysis of Hospital Episodes
Authors: G Hirschfield, L Vale, G Mells, D Shapiro, D Jones
Journal: Gut (2016)

<h3>Introduction</h3> The advent of new therapies for patients with primary biliary cirrhosis (PBC, also known as primary biliary cholangitis) highlights the need to understand the current health burden of PBC. This analysis assesed the frequency and nature of hospitalisations associated with PBC. <h3>Methods</h3> UK-PBC analysed all records from 2009 through 2014 in the Hospital Episodes Statistics database, containing information on all hospitalisation across the National Health Service in England, where the ICD-10 code for PBC (K74.3) appeared as a primary or secondary diagnosis. We characterised primary diagnosis for each hospitalisation. <h3>Results</h3> There were 21,275 admissions with a PBC code over the 5 year observational period covering 1631 unique ICD-10s listed as the primary hospitalisation code. PBC was the primary code for 17% of admissions. The number of relevant hospitalisations increased from 3368 in 2009/2010 to 4995 in 2013/2014. The number per 100,000 hospitalisations increased from 23 to 32 over this period (Figure). The increase was almost completely driven by hospitalisations for which PBC was a secondary diagnosis. Liver transplants represented 5–10% of admissions with PBC as a primary code, and 1–2% of any PBC-related admission. The top 20 primary diagnoses when PBC is secondary included known sequelae of PBC: ascites (1.9% of total admissions), varices (1.3%), and liver cancer (1.3%). Remaining codes included: anaemia (iron deficiency and unspecified; 2.9%); respiratory (pneumonia, COPD and lower respiratory infections; 3.0%); osteoporosis and fractures (1.9%); and various abdominal (unspecified abdominal pain, gastritis and gastroenteritis; 1.5%). <h3>Conclusion</h3> Our UK-PBC data confirms a significant clinical need for patients with PBC, including a rising healthcare burden attributed to disease. The increase in PBC-related diagnoses may be due to more accurate coding, greater co-morbidity as the result of increased longevity, or may represent the true impact of disease. New therapies preventing the progression of PBC to end-stage cirrhosis, and its complications, may help to reduce this rising burden. <h3>Disclosure of Interest</h3> None Declared
Prognostic Impact of Ikaros (IKZF1) Gene Alterations In Childhood ALL Treated with ALL IC-BFM 2002 Protocol: A Comparison of Gene Expression and Genomic-Based Methods.
Authors: Jana Volejnikova, Ester Mejstrikova, Karel Svojgr, Jan Stary, Jan Trka, Eva Fronkova
Journal: Blood (2010)
A Phase I/II Study of Xcellerated T Cells™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Authors: David Siegel, Ravi Vij, Robert A. Vescio, Ivan M. Borrello, Thomas G. Martin, James R. Berenson, Christophe Ferrand, Fatimit Janmohamed, Ronald J. Berenson, Mark W. Frohlich
Journal: Blood (2004)
ThaDD-V Treatment for Patients with Relapsed/Refractory Multiple Myeloma: A Feasibility/Activity Study.
Authors: Massimo Offidani, Claudia Polloni, Laura Corvatta, Maria-Novella Piersantelli, Anna Mele, Massimo Catarini, Marino Brunori, Mario Ferranti, Barbara Amoroso, Pietro Leoni
Journal: Blood (2007)
Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCl for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Authors: Omar S. Aljitawi, Sunil Abhyankar, Siddhartha Ganguly, Karen Wolfe, Kelly Daniels, Ron Marks, Mike Ferree, J.D. Pipkin, Joseph McGuirk
Journal: Blood (2011)
Hypoplastic Acute Myeloid Leukemia.
Authors: Hye-Won Park, Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Miee Seol, Young-Shin Lee, Seong-Gil Ryu, Keun Hee Kim, Seongsoo Jang, Eul-Joo Seo, Chan-Jeoung Park, Hyun-Sook Chi, Jung-Shin Lee, M. Wookun Kim, Kyoo Hyung Lee
Journal: Blood (2006)
Genetic Elimination of Prothrombin in Adult Mice Results in Fatal Spontaneous Hemorrhage in the Heart and Central Nervous System
Authors: Eric S. Mullins, Keith W. Kombrinck, Kathryn E. Talmage, Maureen A. Shaw, David P. Witte, Joni M. Ullman, Sandra J. Degen, William Sun, Matthew Flick, Jay Degen
Journal: Blood (2008)
A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery
Authors: Athena Kritharis, J. Tyson McDonald, Afshin Beheshti, Monika Pilichowska, Kristine Burgess, Luisel Ricks-Santi, Elizabeth McNiel, Ravi Dashnamoorthy, Andrew M. Evens
Journal: Blood (2015)
A Small, Sacred Space
Authors: Lawrence J. Hergott
Journal: Annals of Internal Medicine (2016)

Ad Libitum15 November 2016A Small, Sacred SpaceLawrence J. Hergott, MDLawrence J. Hergott, MDFrom Center for Bioethics and Humanities, University of Colorado School of Medicine, Denver, Colorado.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M16-1517 Audio Reading - “A Small, Sacred Space” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "A Small, Sacred Space," by L.J. Hergott. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail When the staples come out,and the bone beneath has healed,and your flowing hair—artfully parted during—covers the scar after,there will be nothing seenof what proceeded.If the silken movementsof your Persian surgeon's handsare allowed to dowhat they crave to do,you will wake upto no important differencebetween who you areand who you are.You will recognize you.But,as you fear,if the misplaced membranein that small, sacred spacecannot yieldat this chiasm of your life,and tragedy attempts to insinuate itself,you may be different.My most fervent wishis to assure your normalcyafter.I cannot.that those of us who love you ... Author, Article, and Disclosure InformationAffiliations: From Center for Bioethics and Humanities, University of Colorado School of Medicine, Denver, Colorado.Current Author Address: Lawrence J. Hergott, MD; e-mail, [email protected]net. PreviousarticleNextarticle Advertisement Audio Reading - “A Small, Sacred Space” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "A Small, Sacred Space," by L.J. Hergott. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 November 2016Volume 165, Issue 10Page: 752KeywordsBoneFearScars ePublished: 15 November 2016 Issue Published: 15 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
MPL SV, a Unique MPN MPL Splice Variant, Provokes a Fulminant Myeloid Leukemia in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera
Authors: Jerry L. Spivak, Donna Marie Williams, Zhizhuang Joe Zhao, Ophelia Rogers, Amy S. Duffield, W. David Hankins, Alison R Moliterno
Journal: Blood (2015)
Molecular Determinants of Decitabine Response in Chronic Myelomonocytic Leukemia
Authors: Alessia Rossi, Kristen Meldi, Ana Belen Valencia Martinez, Omar Abdel-Wahab, Jean Baptiste Micol, Qin Tingting, Francesca Buchi, Erico Masala, Alessandro Sanna, Bernardino Allione, Monia Lunghi, Francesco Onida, Antonella Poloni, Emanuele Angelucci, Carlo Finelli, Alessandro Levis, Daniela Gioia, Maria E Figueroa, Valeria Santini
Journal: Blood (2014)
Titin-truncating variants affect heart function in disease cohorts and the general population
Authors: Sebastian Schafer, Antonio de Marvao, Eleonora Adami, Lorna R Fiedler, Benjamin Ng, Ester Khin, Owen J L Rackham, Sebastiaan van Heesch, Chee J Pua, Miao Kui, Roddy Walsh, Upasana Tayal, Sanjay K Prasad, Timothy J W Dawes, Nicole S J Ko, David Sim, Laura L H Chan, Calvin W L Chin, Francesco Mazzarotto, Paul J Barton, Franziska Kreuchwig, Dominique P V de Kleijn, Teresa Totman, Carlo Biffi, Nicole Tee, Daniel Rueckert, Valentin Schneider, Allison Faber, Vera Regitz-Zagrosek, Jonathan G Seidman, Christine E Seidman, Wolfgang A Linke, Jean-Paul Kovalik, Declan O'Regan, James S Ware, Norbert Hubner, Stuart A Cook
Journal: Nature Genetics (2016)
Mesenchymal Cancer Cells Can Arise from Ex Vivo Modified Mesenchymal Stem Cells.
Authors: Jakub Tolar, Mark J. Osborn, Angela Panoskaltsis-Mortari, Ron T. McElmurry, Scott Bell, Lily Xia, Megan Riddle, Tania M. Schroeder, Jennifer J. Westendorf, R. Scott McIvor, LeAnn Oseth, Betsy Hirsch, Stephen R. Yant, Mark A. Kay, Alexandra Peister, Darwin J. Prockop, Bruce R. Blazar
Journal: Blood (2005)
Multivalent Targeting Based Delivery of Therapeutic Peptide using AP1-ELP Carrier for Effective Cancer Therapy
Authors: Vijaya Sarangthem, Yunjae Kim, Thoudam Debraj Singh, Bo-Yeon Seo, Sun-Ha Cheon, Young-Jin Lee, Byung-Heon Lee, Rang-Woon Park
Journal: Theranostics (2016)

Elastin-like polypeptide (ELP)-based drug delivery has been utilized for various applications including cancer therapies for many years.Genetic incorporation of internalization ligands and cell-targeting peptides along with ELP polymer enhanced tumor accumulation and retention time as well as stability and activities of the drug conjugates.Herein, we described a unique delivery system comprised of genetically engineered ELP incorporated with multiple copies of IL-4 receptor targeting peptide (AP1) periodically and proapoptotic peptide (KLAKLAK)2 referred to as AP1-ELP-KLAK.It triggered thermal-responsive self-assembly into a nanoparticle-like structure at physiological body temperature and stabilized its helical conformation, which is critical for its membrane-disrupting activities.Increased IL-4 receptor specific cellular internalization was associated with the enhanced cytotoxic effect of (KLAKLAK)2 peptide.Additionally, multivalent presentation of targeting ligands by AP1-ELP-KLAK significantly enhanced intratumoral localization and prolonged the retention time compared to ELP-KLAK, non-targeted control.Systemic administration of AP1-ELP-KLAK significantly inhibited tumor growth by provoking cell apoptosis in various tumor xenograft models without any specific organ toxicity.Thus, our newly designed AP1-ELP-KLAK polymer nanoparticle is a promising candidate for effective cancer therapy and due to the simple preparative procedures of ELPs, this platform can be used as a good carrier for tumor-specific delivery of other therapeutics.
Efficacy of Reduced Induction Chemotherapy and Early Transplantation in ALL Patients
Authors: Ardeshir Ghavamzadeh, Amir Hooshang Pourkhani, Kamran Alimoghaddam, Mohammadreza Ostadali Dehaghi, Amir Ali Hamidieh, Seied Asadollah Mousavi, Roshanak Derakhshandeh, Arash Jalali, Mahdi Jalili, Mohamad Jahani
Journal: Blood (2011)
A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer
Authors: Pierre Adumeau, Kathryn E. Carnazza, Christian Brand, Sean D. Carlin, Thomas Reiner, Brian J. Agnew, Jason S. Lewis, Brian M. Zeglis
Journal: Theranostics (2016)

The complementary nature of positron emission tomography (PET) and near-infrared fluorescence (NIRF) imaging makes the development of strategies for the multimodal PET/NIRF imaging of cancer a very enticing prospect. Indeed, in the context of colorectal cancer, a single multimodal PET/NIRF imaging agent could be used to stage the disease, identify candidates for surgical intervention, and facilitate the image-guided resection of the disease. While antibodies have proven to be highly effective vectors for the delivery of radioisotopes and fluorophores to malignant tissues, the use of radioimmunoconjugates labeled with long-lived nuclides such as 89Zr poses two important clinical complications: high radiation doses to the patient and the need for significant lag time between imaging and surgery. In vivo pretargeting strategies that decouple the targeting vector from the radioactivity at the time of injection have the potential to circumvent these issues by facilitating the use of positron-emitting radioisotopes with far shorter half-lives. Here, we report the synthesis, characterization, and in vivo validation of a pretargeted strategy for the multimodal PET and NIRF imaging of colorectal carcinoma. This approach is based on the rapid and bioorthogonal ligation between a trans-cyclooctene- and fluorophore-bearing immunoconjugate of the huA33 antibody (huA33-Dye800-TCO) and a 64Cu-labeled tetrazine radioligand (64Cu-Tz-SarAr). In vivo imaging experiments in mice bearing A33 antigen-expressing SW1222 colorectal cancer xenografts clearly demonstrate that this approach enables the non-invasive visualization of tumors and the image-guided resection of malignant tissue, all at only a fraction of the radiation dose created by a directly labeled radioimmunoconjugate. Additional in vivo experiments in peritoneal and patient-derived xenograft models of colorectal carcinoma reinforce the efficacy of this methodology and underscore its potential as an innovative and useful clinical tool.
Excellent Outcomes in Children and Young Adults Using Reduced-Intensity Conditioning for Patients with Inborn Errors of Immunity, Hematopoiesis, and Metabolism with Single-Unit Cord Blood or Bone Marrow
Authors: Mark Vander Lugt, Hey Jin Chong, Xiaohua Chen, Randy M. Windreich, Rakesh Goyal, Maria Escolar, Paul Szabolcs
Journal: Blood (2015)
SAT0425 Does Weight in The Offspring of People with A Total Knee Replacement for Severe Primary Knee Osteoarthritis Have A More Detrimental Effect on Knee Cartilage and Pain? A 10-Year Prospective Study
Authors: F. Pan, L. Blizzard, J. Tian, F. Cicuttini, T. Winzenberg, C. Ding, G. Jones
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although being overweight or obese is an important risk factor for the development of knee osteoarthritis (OA), the complex interplay between weight and genetic factors on the early-onset knee OA is still unclear. <h3>Objectives</h3> To determine the effects of weight on knee cartilage volume, defects and knee pain over 10 years in offspring having at least one parent with a total knee replacement for severe primary knee OA and in controls with no family history of knee OA. <h3>Methods</h3> 372 participants (186 offspring and 186 controls) aged from 26–61 years were recruited at baseline, and followed at 2.3 (Phase 2) and 10.2 (Phase 3) years later. T1-weighted magnetic resonance imaging (MRI) of the right knee was used to measure cartilage volume and defects at each time-point. Knee pain was only assessed at Phase 2 and Phase 3 using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Data were analysed using mixed-effects model with adjustment for potential confounders. <h3>Results</h3> Study participants were middle-age adults (mean age 45 years and mean weight of 77.5 kg) at baseline. In multivariable analysis, increasing body weight was negatively associated with medial tibiofemoral cartilage volume (β=-0.28 ml, per 1 SD increase, 95% CI -0.49 to -0.07) and the presence of medial tibiofemoral cartilage defects (OR=1.70, per 1 SD increase, 95% CI 1.20 to 2.33) in offspring over 10.2 years. Similar associations were observed for lateral tibiofemoral cartilage volume (β=-0.19 ml, P=0.059), and defects (OR=1.56, P=0.050). Over 7.9 years, body weight was positively associated with total knee pain (β=1.78, per 1 SD increase, 95% CI 0.49 to 3.06) and all pain subscales (β=0.36 to 0.58, all P&lt;0.05) apart from sitting and standing in offspring while adjusting for potential confounders and knee structural factors. There were no statistically significant associations between weight, and cartilage volume or defects or pain in controls (all P&gt;0.05). <h3>Conclusions</h3> Body weight is associated with knee cartilage volume, defects and pain in offspring of parent with primary knee OA but not in controls, suggesting an interplay between genetic factors and overweight/obesity in the pathogenesis of early knee OA. <h3>Disclosure of Interest</h3> None declared
Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.
Authors: Laurie H. Sehn, David A Macdonald, Sheldon H. Rubin, Guy Cantin, Morel Rubinger, Bernard Lemieux, Sanraj Basi, Kevin R Imrie, Randy D. Gascoyne, Bingshu Chen, Marina Djurfeldt, Lois Shepherd, Stephen Couban, Michael Crump
Journal: Blood (2009)
Influence of Glutathione S-Transferase A1 and P1 Polymorphisms on the Outcome of Hematopoietic Stem Cell Transplantation with Busulfan Based Conditioning Regimen In Children.
Authors: Ji Won Lee, Hyoung Jin Kang, Yen Ju Yuk, Mi Kyoung Jang, Eun Jong Han, Nam Hee Kim, Hyery Kim, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn
Journal: Blood (2010)
Efficient Stroke Prevention Based on Early Detection of Cerebral Vasculopathy by Transcranial Doppler: The Creteil Newborn-Screened Sickle Cell Cohort.
Authors: Francoise Bernaudin, Suzanne Verlhac, Lena Coic, Emmanuelle Lesprit, Cecile Arnaud, Annie Kamdem, Josiane Bardakdjian, Christophe Delacourt
Journal: Blood (2006)
Leukemia Proto-Oncoprotein MLL Forms a SET1 like Complex with Menin to Regulate Hox Gene Expression.
Authors: Akihiko Yokoyama, Zhong Wang, Joanna Wysocka, Mrinmoy Sanyal, Deborah J. Aufiero, Issay Kitabayashi, Winship Herr, Michael L. Cleary
Journal: Blood (2004)
Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies
Authors: Heather K Webb, Hao Chen, Albert S Yu, Sissy Peterman, Leanne Holes, Brian Lannutti, Langdon L. Miller, Roger G Ulrich
Journal: Blood (2010)
C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis
Authors: Brisa S Fernandes, Johann Steiner, Marc L Molendijk, Seetal Dodd, Patricia Nardin, Carlos-Alberto Gonçalves, Felice Jacka, Cristiano A Köhler, Chandan Karmakar, André F Carvalho, Michael Berk
Journal: The Lancet Psychiatry (2016)
Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
Authors: Ravi Vij, Jonathan L. Kaufman, Andrzej J Jakubowiak, Michael Wang, Sundar Jagannath, Vishal Kukreti, Kevin T. McDonagh, Melissa Alsina, Nizar J Bahlis, Andrew R Belch, Frederic J. Reu, Nashat Y. Gabrail, Jeffrey Matous, David H. Vesole, Robert Z. Orlowski, Sandra Wear, Lori Kunkel, Alvin F. Wong, Peter Lee, Keith Stewart
Journal: Blood (2011)